CHLSN

Summary

CHLSN (cholesin, HGNC:22421) is a protein-coding gene on chromosome 7p22.3, encoding Protein cholesin (Q9BRJ6). Hormone secreted from the intestine in response to cholesterol, where it acts to inhibit cholesterol synthesis in the liver and VLDL secretion,leading to a reduction in circulating cholesterol levels.

Enables hormone activity. Involved in negative regulation of cholesterol biosynthetic process. Is active in extracellular space.

Source: NCBI Gene 84310 — RefSeq curated summary.

At a glance

• GWAS associations: 17
• Clinical variants (ClinVar): 221 total
• Druggable target: yes
• MANE Select transcript: NM_001318252

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:22421
Approved symbol	CHLSN
Name	cholesin
Location	7p22.3
Locus type	gene with protein product
Status	Approved
Aliases	MGC11257, YCR016W
Ensembl gene	ENSG00000146540
Ensembl biotype	protein_coding
OMIM	621174
Entrez	84310

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 8 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000357429, ENST00000397098, ENST00000397100, ENST00000412051, ENST00000444428, ENST00000465681, ENST00000488073, ENST00000491163, ENST00000853130, ENST00000853131

RefSeq mRNA: 11 — MANE Select: NM_001318252 NM_001134395, NM_001134396, NM_001318252, NM_001350968, NM_001350969, NM_001424325, NM_001424326, NM_001424327, NM_001424329, NM_001424333, NM_032350

CCDS: CCDS5320

Canonical transcript exons

ENST00000397098 — 5 exons

Exon	Start	End
ENSE00001034888	1127257	1127386
ENSE00001527278	997006	997804
ENSE00001564167	1137315	1138247
ENSE00003459006	1000470	1000551
ENSE00003573128	1009950	1010143

Expression profiles

Bgee: expression breadth ubiquitous, 243 present calls, max score 98.18.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 59.9860 / max 243.8719, expressed in 1823 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
82401	32.8481	1810
82403	20.8245	1764
82400	4.3539	1569
82402	1.9595	923

Top tissues by expression

254 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adenohypophysis	UBERON:0002196	98.18	gold quality
right coronary artery	UBERON:0001625	97.24	gold quality
pituitary gland	UBERON:0000007	96.85	gold quality
anterior cingulate cortex	UBERON:0009835	96.71	gold quality
right frontal lobe	UBERON:0002810	96.68	gold quality
amygdala	UBERON:0001876	96.62	gold quality
apex of heart	UBERON:0002098	96.49	gold quality
sural nerve	UBERON:0015488	96.49	gold quality
popliteal artery	UBERON:0002250	96.28	gold quality
tibial artery	UBERON:0007610	96.27	gold quality
Brodmann (1909) area 9	UBERON:0013540	96.21	gold quality
putamen	UBERON:0001874	95.87	gold quality
nucleus accumbens	UBERON:0001882	95.74	gold quality
tibial nerve	UBERON:0001323	95.70	gold quality
aorta	UBERON:0000947	95.65	gold quality
body of pancreas	UBERON:0001150	95.61	gold quality
mucosa of stomach	UBERON:0001199	95.52	gold quality
descending thoracic aorta	UBERON:0002345	95.50	gold quality
right lobe of thyroid gland	UBERON:0001119	95.45	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	95.44	gold quality
left coronary artery	UBERON:0001626	95.42	gold quality
left lobe of thyroid gland	UBERON:0001120	95.27	gold quality
right atrium auricular region	UBERON:0006631	95.15	gold quality
ascending aorta	UBERON:0001496	95.09	gold quality
caudate nucleus	UBERON:0001873	95.09	gold quality
hypothalamus	UBERON:0001898	95.09	gold quality
thoracic aorta	UBERON:0001515	95.03	gold quality
coronary artery	UBERON:0001621	94.96	gold quality
prefrontal cortex	UBERON:0000451	94.95	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.89	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-HCAD-4	yes	57.15
E-ANND-3	yes	11.83

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

11 targeting CHLSN, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-520F-5P	99.34	70.40	1632
HSA-MIR-3675-3P	99.09	67.70	968
HSA-MIR-1301-3P	98.64	68.27	1071
HSA-MIR-7156-3P	98.25	67.66	859
HSA-MIR-4691-3P	98.11	66.83	1204
HSA-MIR-3173-5P	97.35	65.82	1282
HSA-MIR-6799-3P	97.35	65.60	1302
HSA-MIR-6742-5P	96.32	64.01	869
HSA-MIR-3937	87.69	61.61	103

Literature-anchored findings (GeneRIF, showing 2)

• Three ubiquitous methylation loci were consistently and strongly associated with type 2 diabetes in Ghanaians: TXNIP, C7orf50 and CPT1A (PMID:30107520)
• A gut-derived hormone regulates cholesterol metabolism. (PMID:38503280)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	zmp:0000000624	ENSDARG00000045254
mus_musculus	Chlsn	ENSMUSG00000053553
rattus_norvegicus	C12h7orf50	ENSRNOG00000001289

Protein

Protein identifiers

Protein cholesin — Q9BRJ6 (reviewed: Q9BRJ6)

All UniProt accessions (4): Q9BRJ6, C9JQV0, H7C0T1, H7C2R9

UniProt curated annotations — full annotation on UniProt →

Function. Hormone secreted from the intestine in response to cholesterol, where it acts to inhibit cholesterol synthesis in the liver and VLDL secretion,leading to a reduction in circulating cholesterol levels. Acts through binding to its receptor, GPR146.

Subcellular location. Secreted.

Tissue specificity. Secreted from the instestine, secretion is induced by feeding and cholesterol absorption.

Induction. Expression is induced by feeding and cholesterol absorption.

RefSeq proteins (12): NP_001127867, NP_001127868, NP_001305181, NP_001337897, NP_001337898, NP_001411254, NP_001411255, NP_001411256, NP_001411258, NP_001411262, NP_001411263, NP_115726 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019327	WKF	Domain

Pfam: PF10180

UniProt features (7 total): modified residue 4, chain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BRJ6-F1	75.36	0.47

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 23, 59, 97, 175

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 128 (showing top): GOBP_NEGATIVE_REGULATION_OF_LIPID_METABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_STEROID_METABOLIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_LIPID_BIOSYNTHETIC_PROCESS, GOBP_NEGATIVE_REGULATION_OF_ALCOHOL_BIOSYNTHETIC_PROCESS, chr7p22, GOBP_REGULATION_OF_LIPID_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_CHOLESTEROL_BIOSYNTHETIC_PROCESS, GOBP_SMALL_MOLECULE_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_LIPID_METABOLIC_PROCESS, KOYAMA_SEMA3B_TARGETS_UP, GOBP_STEROID_BIOSYNTHETIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_LIPID_BIOSYNTHETIC_PROCESS, ZHU_CMV_ALL_DN, GOBP_REGULATION_OF_STEROID_BIOSYNTHETIC_PROCESS

GO Biological Process (4): negative regulation of cholesterol biosynthetic process (GO:0045541), adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway (GO:0007193), regulation of cholesterol biosynthetic process (GO:0045540), positive regulation of cholesterol biosynthetic process (GO:0045542)

GO Molecular Function (3): RNA binding (GO:0003723), hormone activity (GO:0005179), protein binding (GO:0005515)

GO Cellular Component (2): obsolete extracellular space (GO:0005615), extracellular region (GO:0005576)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cholesterol biosynthetic process	3
regulation of cholesterol biosynthetic process	2
negative regulation of cholesterol metabolic process	1
negative regulation of sterol biosynthetic process	1
negative regulation of alcohol biosynthetic process	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
adenylate cyclase inhibitor activity	1
regulation of cholesterol metabolic process	1
regulation of sterol biosynthetic process	1
regulation of alcohol biosynthetic process	1
positive regulation of cholesterol metabolic process	1
positive regulation of sterol biosynthetic process	1
positive regulation of alcohol biosynthetic process	1
nucleic acid binding	1
receptor ligand activity	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1260 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CHLSN	MAK16	Q9BXY0	490
CHLSN	CFAP74	Q9C0B2	468
CHLSN	TMA16	Q96EY4	466
CHLSN	SLC22A23	A1A5C7	449
CHLSN	GOLGA8CP	A6NN73	419
CHLSN	ZNF705A	Q6ZN79	418
CHLSN	EME2	A4GXA9	416
CHLSN	RNGTT	O60942	374
CHLSN	GOLGA6L6	A8MZA4	368
CHLSN	ZAR1	Q86SH2	365
CHLSN	MYO19	Q96H55	359
CHLSN	GOLGA6L1	Q8N7Z2	358
CHLSN	STON2	Q8WXE9	355
CHLSN	GALNT9	Q9HCQ5	349
CHLSN	RASA3	Q14644	348

IntAct

176 interactions, top by confidence:

A	B	Type	Score
CHLSN	THAP1	psi-mi:“MI:0915”(physical association)	0.720
THAP1	CHLSN	psi-mi:“MI:0915”(physical association)	0.720
PTK2	TGFB1I1	psi-mi:“MI:0914”(association)	0.680
LIN28A	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
NPM1	MPHOSPH10	psi-mi:“MI:0914”(association)	0.610
GRN	CHLSN	psi-mi:“MI:0915”(physical association)	0.560
CHLSN	WFS1	psi-mi:“MI:0915”(physical association)	0.560
HTT	CHLSN	psi-mi:“MI:0915”(physical association)	0.560
RPL28	MAGEB2	psi-mi:“MI:0914”(association)	0.560
CHLSN	RPL14	psi-mi:“MI:0914”(association)	0.530
RPL37A	MPHOSPH10	psi-mi:“MI:0914”(association)	0.530
ZC3HAV1	KHNYN	psi-mi:“MI:0914”(association)	0.530
RPL30	RRP8	psi-mi:“MI:0914”(association)	0.530
MAGEB2	GTPBP10	psi-mi:“MI:0914”(association)	0.530
CHLSN	tax	psi-mi:“MI:0915”(physical association)	0.490
tax	CHLSN	psi-mi:“MI:0915”(physical association)	0.490
H3C1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.410
CHLSN	ALDH1B1	psi-mi:“MI:0915”(physical association)	0.400
	GNAT3	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (218): C7orf50 (Two-hybrid), C7orf50 (Affinity Capture-MS), C7orf50 (Affinity Capture-MS), C7orf50 (Affinity Capture-MS), C7orf50 (Affinity Capture-MS), C7orf50 (Affinity Capture-MS), C7orf50 (Two-hybrid), C7orf50 (Affinity Capture-MS), C7orf50 (Reconstituted Complex), C7orf50 (Affinity Capture-MS), C7orf50 (Affinity Capture-MS), C7orf50 (Affinity Capture-MS), C7orf50 (Affinity Capture-MS), C7orf50 (Affinity Capture-MS), C7orf50 (Affinity Capture-MS)

ESM2 similar proteins: B0K019, B2KF05, D3ZQL6, D4A615, D4ACP5, E1BBG2, O15037, O43159, O94762, P46087, Q07G43, Q15477, Q4KLL9, Q5REG4, Q5T124, Q5TKR9, Q5U4F0, Q5ZLK6, Q60739, Q6AXX1, Q6NZL6, Q6NZR5, Q6PFD6, Q6ZQF7, Q7L2J0, Q80U38, Q80V91, Q8BGT6, Q8BHW9, Q8BZ21, Q8C0J6, Q8C2K5, Q8CFK6, Q8IV53, Q8IY33, Q8K1S6, Q8K3A9, Q8N3F8, Q8N9I9, Q8TE77

Diamond homologs: Q5I0E3, Q9BRJ6, Q9CXL3

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SMURF1	unknown	C7orf50	ubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 194 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Peptide chain elongation	21	20.7×	2e-20
Viral mRNA Translation	21	20.7×	2e-20
PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA	21	20.4×	2e-20
Selenocysteine synthesis	21	19.6×	5e-20
Eukaryotic Translation Termination	21	19.6×	5e-20
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	21	19.2×	6e-20
ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA	21	19.2×	6e-20
Formation of a pool of free 40S subunits	22	19.1×	2e-20

GO biological processes:

GO term	Partners	Fold	FDR
cytoplasmic translation	22	23.4×	2e-21
ribosomal large subunit biogenesis	7	17.8×	2e-05
translation	23	13.6×	5e-17
ribosomal small subunit biogenesis	10	13.1×	1e-06
rRNA processing	14	11.4×	8e-09

Disease & clinical

Clinical variants and AI predictions

ClinVar

221 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	178
Likely benign	18
Benign	7

Top pathogenic / likely-pathogenic (0)

SpliceAI

4199 predictions. Top by Δscore:

Variant	Effect	Δscore
7:1000547:CCCAT:C	acceptor_gain	1.0000
7:1000548:CCAT:C	acceptor_gain	1.0000
7:1000548:CCATC:C	acceptor_gain	1.0000
7:1000549:CAT:C	acceptor_gain	1.0000
7:1000549:CATC:C	acceptor_gain	1.0000
7:1000552:C:CC	acceptor_gain	1.0000
7:1055481:AAGGT:A	donor_loss	1.0000
7:1055482:AGGTG:A	donor_loss	1.0000
7:1055484:GT:G	donor_loss	1.0000
7:1127251:CCTTA:C	donor_loss	1.0000
7:1127252:CTTAC:C	donor_loss	1.0000
7:1127253:TTA:T	donor_loss	1.0000
7:1127254:TA:T	donor_loss	1.0000
7:1127255:A:AC	donor_gain	1.0000
7:1127255:A:AG	donor_loss	1.0000
7:1127256:C:CC	donor_gain	1.0000
7:1127382:CCATC:C	acceptor_gain	1.0000
7:1127383:CATC:C	acceptor_gain	1.0000
7:1127383:CATCC:C	acceptor_gain	1.0000
7:1127384:ATC:A	acceptor_gain	1.0000
7:1127385:TC:T	acceptor_gain	1.0000
7:1127386:CC:C	acceptor_gain	1.0000
7:1127386:CCTGC:C	acceptor_loss	1.0000
7:1127387:C:CC	acceptor_gain	1.0000
7:1127387:C:CG	acceptor_loss	1.0000
7:1127388:T:C	acceptor_loss	1.0000
7:1127393:C:CT	acceptor_gain	1.0000
7:997803:ACCTG:A	acceptor_loss	1.0000
7:997806:T:A	acceptor_loss	1.0000
7:1000465:CACA:C	donor_loss	0.9900

AlphaMissense

1232 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:1000521:A:C	F118L	0.998
7:1000521:A:T	F118L	0.998
7:1000523:A:G	F118L	0.998
7:1000522:A:G	F118S	0.991
7:1000522:A:C	F118C	0.987
7:1000527:C:A	W116C	0.986
7:1000527:C:G	W116C	0.986
7:997787:G:C	F141L	0.986
7:997787:G:T	F141L	0.986
7:997789:A:G	F141L	0.986
7:1000498:A:T	L126H	0.983
7:1000529:A:G	W116R	0.981
7:1000529:A:T	W116R	0.981
7:1000523:A:C	F118V	0.979
7:997767:A:G	L148P	0.979
7:1000515:C:A	K120N	0.978
7:1000515:C:G	K120N	0.978
7:997803:A:T	V136D	0.978
7:1000498:A:G	L126P	0.977
7:997723:C:G	A163P	0.977
7:997771:A:C	Y147D	0.977
7:1000523:A:T	F118I	0.975
7:1000506:C:A	Q123H	0.973
7:1000506:C:G	Q123H	0.973
7:1000495:A:G	L127P	0.971
7:1000502:A:G	W125R	0.971
7:1000502:A:T	W125R	0.971
7:997758:A:G	L151P	0.971
7:1000498:A:C	L126R	0.969
7:997771:A:G	Y147H	0.969

dbSNP variants (sampled 300 via entrez): RS1000005933 (7:1007706 T>A,C), RS1000011906 (7:1096458 G>A,C), RS1000046278 (7:1095532 C>T), RS1000090736 (7:1092673 C>T), RS1000090921 (7:1125086 G>A), RS1000095024 (7:1029555 C>T), RS1000099848 (7:1063601 G>A), RS1000105732 (7:978523 A>G), RS1000160165 (7:994418 C>A,G,T), RS1000172939 (7:1053060 G>T), RS1000174950 (7:979315 G>A), RS1000249512 (7:1070863 C>T), RS1000250523 (7:1021909 A>C), RS1000254419 (7:979290 C>T), RS1000257716 (7:1099195 G>A)

Disease associations

OMIM: gene MIM:621174 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST000785_22	Longevity	1.000000e-06
GCST003678_19	C-reactive protein levels or total cholesterol levels (pleiotropy)	3.000000e-09
GCST003819_2	Endometriosis	3.000000e-06
GCST006612_32	LDL cholesterol	2.000000e-16
GCST006614_134	Total cholesterol levels	8.000000e-19
GCST008084_165	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	2.000000e-08
GCST008084_93	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	1.000000e-08
GCST010204_188	Low density lipoprotein cholesterol levels	6.000000e-12
GCST010242_139	HDL cholesterol levels	2.000000e-12
GCST010242_291	HDL cholesterol levels	3.000000e-26
GCST010245_81	LDL cholesterol levels	1.000000e-08
GCST012489_75	Heel bone mineral density x serum urate levels interaction	4.000000e-09
GCST90002385_174	High light scatter reticulocyte count	2.000000e-16
GCST90002392_710	Mean corpuscular volume	5.000000e-12
GCST90002397_496	Mean spheric corpuscular volume	1.000000e-12
GCST90002405_215	Reticulocyte count	4.000000e-18
GCST90002406_234	Reticulocyte fraction of red cells	7.000000e-17

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004458	C-reactive protein measurement
EFO:0004574	total cholesterol measurement
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004329	alcohol drinking
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004531	urate measurement
EFO:0009270	heel bone mineral density
EFO:0007986	reticulocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066340 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 4 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.82	Kd	15.12	nM	CHEMBL3752910
7.82	ED50	15.12	nM	CHEMBL3752910

PubChem BioAssay actives

1 with measured affinity, of 4 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147974: Binding affinity to human C7orf50 incubated for 45 mins by Kinobead based pull down assay	kd	0.0151	uM

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation, affects expression	5
bisphenol A	affects methylation, decreases expression, decreases methylation, increases expression	4
Benzo(a)pyrene	decreases expression, increases methylation	3
sodium arsenite	decreases expression, increases expression	2
Tobacco Smoke Pollution	decreases methylation	2
Aflatoxin B1	increases methylation	2
GSK-J4	increases expression	1
FR900359	increases phosphorylation	1
bisphenol F	affects cotreatment, increases methylation	1
cobaltous chloride	decreases expression	1
aflatoxin B2	increases methylation	1
cyclic 3’,5’-uridine monophosphate	affects binding	1
di-n-butylphosphoric acid	affects expression	1
K 7174	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
ICG 001	increases expression	1
bisphenol S	decreases methylation	1
jinfukang	increases expression	1
LDN 193189	decreases expression, affects cotreatment	1
(+)-JQ1 compound	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Arsenic	affects expression	1
Benzene	increases expression	1
Caffeine	increases phosphorylation	1
Dimethyl Sulfoxide	increases expression	1
Diuron	decreases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ivermectin	decreases expression	1
Quercetin	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651016	Binding	Binding affinity to human C7orf50 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.